
    
      This study is an open-label, partially randomized, 4-period, 5-treatment study in healthy
      male subjects, performed at a single study center. All subjects will receive the 4 of the 5
      treatments. The IV infusion will be fixed as the first treatment (Period 1), the Monodose
      inhaler will be fixed as the second treatment (Period 2) and the oral formulation will be
      fixed as the fourth treatment (Period 4). During Period 3, subjects are split into 2 equal
      cohorts, multiple-dose DPI and pMDI.
    
  